

GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

Estado	Tipo de Participantes	Rangos de Edad
EC Finalizado	No aportado	Mayores de 64 , Adultos (18-64 años)
Género	Fases	Participantes esperados
Ambos	Fase I , Fase II	84
Resultados	Bajo nivel intervención	Enfermedad rara
Sin resultados	No	No
Cobertura geográfica	Ámbitos del ensayo	Terapia avanzada
Sin determinar	seguridad, eficacia, farmacocinética, farmacodinámica	NO

Información

Identificador	Cod. Protocolo
2023-507086-26-00 (CTIS)	GCT3014-01

Transicionado 2020-003781-40

Área terapéutica

Enfermedades [C] - Cáncer [C04]

Enfermedad investigada

Relapsed or Refractory Multiple Myeloma (RRMM)
Diffuse Large B Cell Lymphoma (DLBCL)
Acute Myeloid Leukemia (AML)

Título Científico

An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

Justificación

No aportado

Objetivo Principal

Determine the RP2D and if reached, the MTD of GEN3014
Evaluate the safety and tolerability of GEN3014
Please refer to the protocol section 3 (Tables 3-2 and 3-3) for the full list of main objectives for the Expansion Part A (GEN3014 Single Cohorts) and Expansion Part B (Randomized H2H) of the study, respectively.

Variables de Evaluación Primaria

- Incidence of DLTs
 - Safety: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), including changes in laboratory values, vital signs, electrocardiograms (ECGs)
 - Tolerability: Dose interruptions, delay, and dose intensity. Please refer to the protocol section 3 (Tables 3-2 and 3-3) for the full list of primary endpoints for the Expansion Part A (GEN3014 Single Cohorts) and Expansion Part B (Randomized H2H) of the study, respectively.
-

Momentos temporales de evaluación primaria

No aportado

Objetivo Secundario

Characterize the PK properties of GEN3014 Evaluate immunogenicity Assess the preliminary anti-tumor activity of GEN3014 Assess the clinical efficacy of GEN3014 Please refer to the protocol section 3 (Tables 3-2 and 3-3) for the full list of secondary objectives for the Expansion Part A (GEN3014 Single Cohorts) and Expansion Part B (Randomized H2H) of the study, respectively.

Variables de Evaluación Secundaria

Noncompartmental PK parameters (if feasible): o Maximum concentration (Cmax) o Time to Cmax (Tmax) o Predose concentration (Ctrough) o Area under the concentration-time curve from time zero to last quantifiable sample (AUC0-last) and from time zero to 168 h (AUC0- 168h) o Accumulation ratios in Cmax (RA,Cmax) and AUC (RA,AUC]. In addition, a population PK modeling approach may be employed.
Anti-GEN3014 antibodies Objective response rate (ORR) Clinical benefit rate (CBR) Duration of response (DOR) Time-to-response (TTR)
Progression-free survival (PFS) Overall survival (OS). Please refer to the protocol section 3 (Tables 3-2 and 3-3) for the full list of secondary endpoints for the Expansion Part A (GEN3014 Single Cohorts) and Expansion Part B (Randomized H2H) of the study, respectively.

Momentos temporales de evaluación secundaria

No aportado

Criterios de Inclusión

1. Must be at least 18 years of age.

Specific Inclusion Criteria for RRMM: 10. Must have documented multiple myeloma as defined by the criteria below and have evidence of disease progression on the most recent prior treatment regimen based on IMWG criteria: Prior documentation of monoclonal plasma cells in the bone marrow 10% or presence of a biopsy-proven plasmacytoma and Measurable disease at baseline as defined by any of the following: - IgG, IgA, IgD, or IgM myeloma: Serum M-protein level 0.5 g/dL (5 g/L) or urine M-protein level 200 mg/24 hours; or - Light chain myeloma: Serum Ig free light chain (FLC) 10 mg/dL and abnormal serum Ig kappa lambda FLC ratio. Participants with RRMM must have exhausted standard therapies, at the investigators discretion.

11. For anti-CD38 mAb-naïve RRMM subjects: Subject received at least 3 prior lines of therapy including a PI and an IMiD in any order, or is double refractory to a PI and an IMiD; or subject received 2 prior lines of therapy if 1 of those lines included a combination of PI and IMiD. Note: Subjects should not have received any anti-CD38 antibody.

12. For anti-CD38 mAb-treated RRMM participants: Participant has received at least 2 prior lines of therapy and must have discontinued daratumumab or isatuximab for at least 4 weeks prior to the first dose of GEN3014. Note: Participants should not have received any other anti-CD38 antibody except daratumumab or isatuximab.

13. Potassium level 3.0 mEq/L (3.0 mmol/L); and corrected serum calcium 14.0 mg/dL (3.5 mmol/L) or free ionized calcium 6.5 mg/dL (1.6 mmol/L).

Specific Inclusion Criteria for R/R AML: 14. Relapsed or refractory AML, both de novo or secondary; must have failed all conventional therapy. Acute promyelocytic leukemia (APL) is excluded from this trial. Note: Relapse is defined by BM blasts 5% in patients who have been in complete remission (CR) previously, or reappearance of blasts in the blood, or development of extramedullary AML. Refractory is defined as not being able to achieve a CR after the initial therapy.

Specific Inclusion Criteria for R/R AML: 15. Subject with relapsed AML who received at least 2 prior therapies for AML with the exception of hydroxyurea.

Specific Inclusion Criteria for R/R AML: 16. Subject with refractory AML who received at least 1 prior line of therapy for AML with the exception of hydroxyurea.

Specific Inclusion Criteria for R/R AML: 17. Subject's life expectancy at Screening is judged to be at least 3 months. Please refer to Protocol sections 5.1.2 and 5.1.3 for the Inclusion Criteria for the Expansion Part A (GEN3014 Single Cohorts) and Expansion Part B (Randomized H2H), respectively

2. Must sign an informed consent form (ICF) prior to any Screening

3. Must have fresh bone marrow samples collected at Screening.

4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score 0,1 or 2

5. Has acceptable laboratory test results during the Screening period

6. A woman of reproductive potential must agree to use adequate contraception during the trial and for 12 months after the last GEN3014 or daratumumab SC administration.

7. A woman of childbearing potential must have a negative serum beta-human chorionic gonadotropin (-hCG) at Screening and additionally, for Expansion Part B, within 72 hours of the first dose of study treatment prior to dosing.

8. A woman must agree not to donate eggs (ova, oocytes) for assisted reproduction during the trial and for 12 months after receiving the last dose of GEN3014 or daratumumab SC.

9. A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control, and all men must also not donate sperm during the trial and for 12 months after receiving the last dose of GEN3014 or daratumumab SC.

Criterios de Exclusión

1. Prior treatment with any anti-CD38 directed therapies (eg. daratumumab, isatuximab, CD38 CAR-T, bispecific Ab)

in anti-CD38 mAb- naive RRMM Cohort. Note: Prior daratumumab or isatuximab exposure is allowed for anti-CD38 mAb-treated RRMM subjects in the Dose Escalation and anti-CD38 mAb-refractory RRMM Cohort in the Expansion Part A. 10. Known history of seropositivity of human immunodeficiency virus (HIV) (Dose Escalation and Expansion Part A) or to be positive for HIV with details in the protocol (Expansion Part B). 11. Currently receiving any other investigational agents. 12. A woman who is pregnant or breast-feeding, or who is planning to become pregnant while enrolled in this trial or within 12 months after the last dose of study treatment. 13. A man who plans to father a child while enrolled in this trial or within 12 months after the last dose of study treatment. Specific Exclusion Criteria for RRMM: 14. Prior allogeneic HSCT. 15. Specific Exclusion Criteria for RRMM: Autologous HSCT within 3 months of the first dose of GEN3014. 16. Specific Exclusion Criteria for R/R AML: <5% blasts in blood or bone marrow at Screening. 17. Specific Exclusion Criteria for R/R AML: Prior autologous HSCT. 18. Specific Exclusion Criteria for R/R AML: Allogeneic HSCT within 3 months of the first dose of GEN3014 19. Specific Exclusion Criteria for R/R AML: Active graft-versus-host-disease requiring immunosuppressive treatment. Any immunosuppressive medication (eg, calcineurin inhibitors) must be stopped 4 weeks prior to the first dose of GEN3014. Please refer to the protocol section 5.2.2 for the full list of Exclusion criteria for the Expansion Part B (Randomized H2H). 2. Treatment with an anti-cancer agent, chemotherapy, radiation therapy, or major surgery within 2 weeks prior to the first dose of study treatment (Dose Escalation and Expansion Part A) or randomization (Expansion Part B). 3. Treatment with an investigational drug within 4 weeks or 5 half-lives, whichever is shorter, prior to the first dose of study treatment (Dose Escalation and Expansion Part A) or randomization (Expansion Part B). 4. Cumulative dose of corticosteroids more than the equivalent of 140 mg of prednisone within 2-week period before the first dose of study treatment (Dose Escalation and Expansion Part A) or maximum cumulative dose of dexamethasone 160 mg within 28 days of randomization (Expansion Part B). 5. Has clinically significant cardiac disease 6. Toxicities from previous anti-cancer therapies have not resolved to baseline levels or to Grade 1 or less except for alopecia and peripheral neuropathy. 7. Primary central nervous system (CNS) tumor or known CNS involvement at Screening. 8. Has known history/positive serology for hepatitis B 9. Known medical history or ongoing hepatitis C infection that has not been cured.

Calendario

(Última actualización: 12/08/2025)

Autorización 12/02/2021	Inicio de Ensayo 29/11/2021	Inclusión Primer Paciente 29/11/2021	Interrumpido No aportado	Reiniciado No aportado
Fin de reclutamiento 10/09/2024	Fin prematuro (España) No aportado	Fin prematuro (Global) No aportado	Fin del ensayo en España 15/10/2024	Fin del ensayo global 01/08/2025

Promotor

Genmab A/S Denmark

Carl Jacobsens Vej 30

Contact Person

Information

+4570202728

clinicaltrials@genmab.com

Monetary support: N/A

Tipo de promotor: Comercial

Ceim

CEIm Parc Tauli

Plaça de la Torre de l'Aigua, s/n 08208 Sabadell

ceic@tauli.cat

937458454-937458451

Centros

Cerrado (15/05/2025)

Clinica Universidad De Navarra

Pamplona

NAVARRA

Oncology

Cerrado (13/12/2024)

Hospital Universitario De Salamanca

Salamanca

SALAMANCA

Hematology

Medicamentos

DARZALEX 1800 mg solution for injection

SOLUTION FOR INJECTION

SUBCUTANEOUS

Código ATC: L01FC01 - DARATUMUMAB

Principios Activos: N/A

Huérfano

Experimental

GEN3014 DP

SOLUTION FOR INFUSION

INTRAVENOUS

Principios Activos: N/A

Experimental

Sin resultados

GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

State
Finished CT

Type of participants
Not provided

Age Ranges
Older than 64 , Adults (18-64 years)

Gender
Both

Phases
Phase I , Phase II

Expected Participants
84

Results
No results

Low level of intervention
No

Rare disease
No

Geographic coverage
Undetermined

Areas of the study
safety, effectiveness, pharmacokinetics,
pharmacodynamics

Advanced therapy
NO

Information

Identifier
2023-507086-26-00 (CTIS)

Protocol Code
GCT3014-01

Transitioned 2020-003781-40

Therapeutic area
Diseases [C] - Cancer [C04]

Investigated Disease
Relapsed or Refractory Multiple Myeloma (RRMM)
Diffuse Large B Cell Lymphoma (DLBCL)
Acute Myeloid Leukemia (AML)

Scientific Title
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies

Rationale

Not provided

Main Objective

Determine the RP2D and if reached, the MTD of GEN3014
Evaluate the safety and tolerability of GEN3014
Please refer to the protocol section 3 (Tables 3-2 and 3-3) for the full list of main objectives for the Expansion Part A (GEN3014 Single Cohorts) and Expansion Part B (Randomized H2H) of the study, respectively.

Primary Endpoints

- Incidence of DLTs
 - Safety: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), including changes in laboratory values, vital signs, electrocardiograms (ECGs)
 - Tolerability: Dose interruptions, delay, and dose intensity. Please refer to the protocol section 3 (Tables 3-2 and 3-3) for the full list of primary endpoints for the Expansion Part A (GEN3014 Single Cohorts) and Expansion Part B (Randomized H2H) of the study, respectively.
-

Temporary moments of secondary assessment

Not provided

Secondary Objective

Characterize the PK properties of GEN3014 Evaluate immunogenicity Assess the preliminary anti-tumor activity of GEN3014 Assess the clinical efficacy of GEN3014 Please refer to the protocol section 3 (Tables 3-2 and 3-3) for the full list of secondary objectives for the Expansion Part A (GEN3014 Single Cohorts) and Expansion Part B (Randomized H2H) of the study, respectively.

Secondary Endpoints

Noncompartmental PK parameters (if feasible):
o Maximum concentration (C_{max})
o Time to C_{max} (T_{max})
o Predose concentration (C_{trough})
o Area under the concentration-time curve from time zero to last quantifiable sample (AUC_{0-last}) and from time zero to 168 h (AUC_{0-168h})
o Accumulation ratios in C_{max} (RA, C_{max}) and AUC (RA, AUC). In addition, a population PK modeling approach may be employed.
Anti-GEN3014 antibodies Objective response rate (ORR) Clinical benefit rate (CBR) Duration of response (DOR) Time-to-response (TTR)
Progression-free survival (PFS) Overall survival (OS). Please refer to the protocol section 3 (Tables 3-2 and 3-3) for the full list of secondary endpoints for the Expansion Part A (GEN3014 Single Cohorts) and Expansion Part B (Randomized H2H) of the study, respectively.

Temporary moments of secondary assessment

Not provided

Inclusion criteria

1. Must be at least 18 years of age.

Specific Inclusion Criteria for RRMM: 10. Must have documented multiple myeloma as defined by the criteria below and have evidence of disease progression on the most recent prior treatment regimen based on IMWG criteria: Prior documentation of monoclonal plasma cells in the bone marrow 10% or presence of a biopsy-proven plasmacytoma and Measurable disease at baseline as defined by any of the following: - IgG, IgA, IgD, or IgM myeloma: Serum M-protein level 0.5 g/dL (5 g/L) or urine M-protein level 200 mg/24 hours; or - Light chain myeloma: Serum Ig free light chain (FLC) 10 mg/dL and abnormal serum Ig kappa lambda FLC ratio. Participants with RRMM must have exhausted standard therapies, at the investigators discretion.

11. For anti-CD38 mAb-naïve RRMM subjects: Subject received at least 3 prior lines of therapy including a PI and an IMiD in any order, or is double refractory to a PI and an IMiD; or subject received 2 prior lines of therapy if 1 of those lines included a combination of PI and IMiD. Note: Subjects should not have received any anti-CD38 antibody.

12. For anti-CD38 mAb-treated RRMM participants: Participant has received at least 2 prior lines of therapy and must have discontinued daratumumab or isatuximab for at least 4 weeks prior to the first dose of GEN3014. Note: Participants should not have received any other anti-CD38 antibody except daratumumab or isatuximab.

13. Potassium level 3.0 mEq/L (3.0 mmol/L); and corrected serum calcium 14.0 mg/dL (3.5 mmol/L) or free ionized calcium 6.5 mg/dL (1.6 mmol/L).

Specific Inclusion Criteria for R/R AML: 14. Relapsed or refractory AML, both de novo or secondary; must have failed all conventional therapy. Acute promyelocytic leukemia (APL) is excluded from this trial. Note: Relapse is defined by BM blasts 5% in patients who have been in complete remission (CR) previously, or reappearance of blasts in the blood, or development of extramedullary AML. Refractory is defined as not being able to achieve a CR after the initial therapy.

Specific Inclusion Criteria for R/R AML: 15. Subject with relapsed AML who received at least 2 prior therapies for AML with the exception of hydroxyurea.

Specific Inclusion Criteria for R/R AML: 16. Subject with refractory AML who received at least 1 prior line of therapy for AML with the exception of hydroxyurea.

Specific Inclusion Criteria for R/R AML: 17. Subject's life expectancy at Screening is judged to be at least 3 months. Please refer to Protocol sections 5.1.2 and 5.1.3 for the Inclusion Criteria for the Expansion Part A (GEN3014 Single Cohorts) and Expansion Part B (Randomized H2H), respectively

2. Must sign an informed consent form (ICF) prior to any Screening

3. Must have fresh bone marrow samples collected at Screening.

4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score 0,1 or 2

5. Has acceptable laboratory test results during the Screening period

6. A woman of reproductive potential must agree to use adequate contraception during the trial and for 12 months after the last GEN3014 or daratumumab SC administration.

7. A woman of childbearing potential must have a negative serum beta-human chorionic gonadotropin (-hCG) at Screening and additionally, for Expansion Part B, within 72 hours of the first dose of study treatment prior to dosing.

8. A woman must agree not to donate eggs (ova, oocytes) for assisted reproduction during the trial and for 12 months after receiving the last dose of GEN3014 or daratumumab SC.

9. A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control, and all men must also not donate sperm during the trial and for 12 months after receiving the last dose of GEN3014 or daratumumab SC.

Exclusion criteria

1. Prior treatment with any anti-CD38 directed therapies (eg. daratumumab, isatuximab, CD38 CAR-T, bispecific Ab)

in anti-CD38 mAb- naive RRMM Cohort. Note: Prior daratumumab or isatuximab exposure is allowed for anti-CD38 mAb-treated RRMM subjects in the Dose Escalation and anti-CD38 mAb-refractory RRMM Cohort in the Expansion Part A. 10. Known history of seropositivity of human immunodeficiency virus (HIV) (Dose Escalation and Expansion Part A) or to be positive for HIV with details in the protocol (Expansion Part B). 11. Currently receiving any other investigational agents. 12. A woman who is pregnant or breast-feeding, or who is planning to become pregnant while enrolled in this trial or within 12 months after the last dose of study treatment. 13. A man who plans to father a child while enrolled in this trial or within 12 months after the last dose of study treatment. Specific Exclusion Criteria for RRMM: 14. Prior allogeneic HSCT. 15. Specific Exclusion Criteria for RRMM: Autologous HSCT within 3 months of the first dose of GEN3014. 16. Specific Exclusion Criteria for R/R AML: <5% blasts in blood or bone marrow at Screening. 17. Specific Exclusion Criteria for R/R AML: Prior autologous HSCT. 18. Specific Exclusion Criteria for R/R AML: Allogeneic HSCT within 3 months of the first dose of GEN3014 19. Specific Exclusion Criteria for R/R AML: Active graft-versus-host-disease requiring immunosuppressive treatment. Any immunosuppressive medication (eg, calcineurin inhibitors) must be stopped 4 weeks prior to the first dose of GEN3014. Please refer to the protocol section 5.2.2 for the full list of Exclusion criteria for the Expansion Part B (Randomized H2H). 2. Treatment with an anti-cancer agent, chemotherapy, radiation therapy, or major surgery within 2 weeks prior to the first dose of study treatment (Dose Escalation and Expansion Part A) or randomization (Expansion Part B). 3. Treatment with an investigational drug within 4 weeks or 5 half-lives, whichever is shorter, prior to the first dose of study treatment (Dose Escalation and Expansion Part A) or randomization (Expansion Part B). 4. Cumulative dose of corticosteroids more than the equivalent of 140 mg of prednisone within 2-week period before the first dose of study treatment (Dose Escalation and Expansion Part A) or maximum cumulative dose of dexamethasone 160 mg within 28 days of randomization (Expansion Part B). 5. Has clinically significant cardiac disease 6. Toxicities from previous anti-cancer therapies have not resolved to baseline levels or to Grade 1 or less except for alopecia and peripheral neuropathy. 7. Primary central nervous system (CNS) tumor or known CNS involvement at Screening. 8. Has known history/positive serology for hepatitis B 9. Known medical history or ongoing hepatitis C infection that has not been cured.

Calendar

(Last Update: 12/08/2025)

Authorization 12/02/2021	Start of Trial 29/11/2021	First patient inclusion 29/11/2021	Halted Not aported	Restarted Not aported
End of recruitment 10/09/2024	Premature end (Spain) Not aported	Premature End (Global) Not aported	Trial end (Spain) 15/10/2024	Trial end (Global) 01/08/2025

Sponsor

Genmab A/S Denmark

Carl Jacobsens Vej 30

Contact Person

Information

+4570202728

clinicaltrials@genmab.com

Monetary support: N/A

Sponsor type: Commercial

Ceim

CEIm Parc Tauli

Plaça de la Torre de l'Aigua, s/n 08208 Sabadell

ceic@tauli.cat

937458454-937458451

Sites

Clinica Universidad De Navarra

Pamplona

NAVARRA

Oncology

Closed (15/05/2025)

Hospital Universitario De Salamanca

Salamanca

SALAMANCA

Hematology

Closed (13/12/2024)

Medication

DARZALEX 1800 mg solution for injection

SOLUTION FOR INJECTION

SUBCUTANEOUS

ATC code: L01FC01 - DARATUMUMAB

Active Principles: N/A

Orphan

Experimental

GEN3014 DP

SOLUTION FOR INFUSION

INTRAVENOUS

Active Principles: N/A

Experimental

No results